<DOC>
	<DOCNO>NCT00357565</DOCNO>
	<brief_summary>RATIONALE : Giving chemotherapy , busulfan , fludarabine , melphalan , donor umbilical cord blood stem cell transplant help stop growth abnormal cancer cell prepare patient 's bone marrow stem cell . When healthy stem cell donor infused patient may help patient 's bone marrow make stem cell , red blood cell , white blood cell , platelet . Sometimes transplanted cell donor make immune response body 's normal cell . Giving cyclosporine mycophenolate mofetil may stop happen . PURPOSE : This phase II trial study well combination chemotherapy follow donor umbilical cord blood transplant work treat infant high-risk acute leukemia myelodysplastic syndrome .</brief_summary>
	<brief_title>Hematopoietic Stem Cell Transplantation Treatment Infant Leukemia</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine incidence engraftment , define achieve donor-derived neutrophil count &gt; 500/mm³ day 42 , infant high-risk acute myeloid leukemia , acute lymphoblastic leukemia , myelodysplastic syndrome treat non-irradiation contain myeloablative condition regimen comprise busulfan , fludarabine , melphalan follow double umbilical cord blood transplantation ( UCBT ) two partially HLA-matched unit . Secondary Objectives - Determine incidence transplant-related mortality ( TRM ) 6 month UCBT - Evaluate pattern chimerism double UCBT - Determine incidence platelet engraftment 1 year UCBT - Determine incidence acute graft-versus-host disease ( GVHD ) grade II-IV grade III-IV day 100 UCBT - Evaluate developmental outcome UCBT Transplant Related Objectives - Determine incidence chronic GVHD 1 year UCBT - Determine survival disease free survival 1 2 year UCBT - Determine incidence relapse 1 2 year UCBT</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>Matched sibling donor ( HLA 8/8 ) , available , unrelated partially HLA match single unit base follow priority : 1st priority : 4/6 match unit , cell dose &gt; 5 x 107 nucleated cells/kg 2nd priority : 5/6 match unit , cell dose &gt; 4 x 107 nucleated cells/kg 3rd priority : 6/6 match unit , cell dose &gt; 3 x 107 nucleated cells/kg Patients age ≤ 3 year diagnosis ( age transplant ) hematological malignancy detail : Acute myeloid leukemia : high risk CR1 evidence : High risk cytogenetics ( 4 ; 11 ) MLL rearrangement ; chromosome 5 , 7 , 19 abnormality ; complex karyotype ( &gt; 5 distinct change ) ; ≥ 2 cycle obtain complete response ( CR ) ; CR2 high ; Preceding myelodysplastic syndrome ( MDS ) ; All patient must CR early relapse ( i.e. , &lt; 15 % blast BM ) . Acute lymphocytic leukemia : high risk CR1 evidence : Highrisk cytogenetic : ( 4 ; 11 ) MLL rearrangement ; hypodiploid ; ( 9 ; 22 ) ; &gt; 1 cycle obtain CR ; CR2 high ; All patient must CR defined hematological recovery , AND &lt; 5 % blast light microscopy within bone marrow cellularity ≥15 % . Myelodysplasia ( MDS ) IPSS Int2 High risk ( i.e . RAEB , RAEBt ) refractory anemia severe pancytopenia high risk cytogenetics . Blasts must &lt; 10 % representative bone marrow aspirate morphology . Persistent rise minimal residual disease ( MRD ) standard chemotherapy regimen : Patients evidence minimal residual disease completion therapy evidence rise MRD therapy . MRD define either flow cytometry ( &gt; 0.1 % residual cell blast gate immune phenotype original leukemic clone ) , molecular technique ( PCR FISH ) conventional cytogenetics ( gbanding ) . New Leukemia Subtypes : A major effort field pediatric hematology identify patient high risk treatment failure patient appropriately stratify either ( less ) intensive therapy . This effort continually ongoing retrospective study identify new disease feature characteristic associated treatment outcome . Therefore , new high risk feature identify write protocol , patient enrol approval two member study committee . Recipients must Lansky score ≥ 50 % acceptable organ function define : Renal : glomerial filtration rate &gt; 60ml/min/1.73m^2 Hepatic : bilirubin , AST/ALT , ALP &lt; 5 x upper limit normal , Pulmonary function : oxygen saturation &gt; 92 % Cardiac : leave ventricular ejection fraction &gt; 45 % . Voluntary write informed consent performance studyrelated procedure part normal medical care . Active infection time transplantation ( include active infection Aspergillus mold within 30 day ) . History HIV infection know positive serology Myeloablative transplant within last 6 month . Evidence active extramedullary disease ( include central nervous system leukemia ) .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>3 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>childhood acute myeloid leukemia remission</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>childhood acute lymphoblastic leukemia remission</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>refractory anemia excess blast transformation</keyword>
	<keyword>refractory anemia excess blast</keyword>
	<keyword>refractory anemia</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>childhood myelodysplastic syndrome</keyword>
</DOC>